Boston Scientific Corp. vs. Daxor Corporation Common Stock
Boston Scientific Corp. (BSX) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| BSX | DXR | |
|---|---|---|
| Market Cap | $63.11 billion | $65.10 million |
| Revenue (TTM) | $21.00 billion | $1.45 million |
| Net Income (TTM) | $3.67 billion | $-7,185,639 |
BSX leads on 3 of 3 size & scale factors.
Valuation
| BSX | DXR | |
|---|---|---|
| P/E Ratio | 17.55 | — |
| Price / Book | 2.51 | 1.80 |
| Price / Sales | 3.01 | 45.01 |
BSX and DXR split the valuation factors evenly.
Profitability
| BSX | DXR | |
|---|---|---|
| Net Margin | 17.47% | -496.81% |
| Return on Equity | 14.58% | -19.84% |
BSX leads on 2 of 2 profitability factors.
Dividend
| BSX | DXR | |
|---|---|---|
| Dividend Yield | — | 0.27% |
BSX and DXR split the dividend factors evenly.
Risk & Sentiment
| BSX | DXR | |
|---|---|---|
| Short Interest | 0.72% | 0.00% |
DXR leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, DXR overview, DXR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.